Insmed says Japan health ministry approves BRINSUPRI for non-cystic fibrosis bronchiectasis

Reuters2026/08/24 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Japan’s MHLW cleared Insmed’s BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis in adults, children aged 12 and older.
Decision based on Phase 3 ASPEN data showing fewer pulmonary exacerbations versus placebo over 52 weeks.
Approval expands BRINSUPRI’s footprint to Japan, adding to existing authorizations in the U.S. and Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240700PR_NEWS_USPR_____NY31663) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Insmed says Japan health ministry approves BRINSUPRI for non-cystic fibrosis bronchiectasis

You may also like

Crypto prices